Ubs Asset Management Americas Inc Maxcyte, Inc. Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Maxcyte, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 203,648 shares of MXCT stock, worth $688,330. This represents 0.0% of its overall portfolio holdings.
Number of Shares
203,648
Previous 230,759
11.75%
Holding current value
$688,330
Previous $904,000
12.39%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding MXCT
# of Institutions
124Shares Held
65.6MCall Options Held
1KPut Options Held
2K-
Cadian Capital Management, LP New York, NY8.19MShares$27.7 Million1.63% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$27.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.78MShares$19.5 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$17 Million7.62% of portfolio
-
Morgan Stanley New York, NY4.82MShares$16.3 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $344M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...